Piper Sandler initiated coverage on Tempus AI with a new price target
$TEM
Computer Software: Programming Data Processing
Technology
Piper Sandler initiated coverage of Tempus AI with a rating of Neutral and set a new price target of $40.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/19/2026 | $100.00 | Outperform | Mizuho |
| 2/17/2026 | $59.00 | Outperform | Robert W. Baird |
| 12/2/2025 | $85.00 | Overweight | Morgan Stanley |
| 10/21/2025 | $88.00 | Buy → Hold | TD Cowen |
| 10/20/2025 | $110.00 | Buy | Canaccord Genuity |
| 9/2/2025 | $90.00 | Buy | H.C. Wainwright |
| 4/21/2025 | $60.00 | Buy | BTIG Research |
| 2/25/2025 | $50.00 → $55.00 | Overweight → Neutral | Analyst |
144 - Tempus AI, Inc. (0001717115) (Subject)
S-8 - Tempus AI, Inc. (0001717115) (Filer)
10-K - Tempus AI, Inc. (0001717115) (Filer)
4 - Tempus AI, Inc. (0001717115) (Reporting)
4 - Tempus AI, Inc. (0001717115) (Reporting)
Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 3, 2026 /CNW/ -- USANewsGroup.com News Commentary -- AI is making its way through the halls of our entire medical system, and the implementation is accelerating at a great pace. The AI medical imaging market is projected to hit nearly $20 billion by 2033, growing at a 34.7% CAGR[1]. Echocardiography alone is forecast to grow to $2.64 billion by 2030 as hospitals demand cardiac platforms that prove economic value alongside clinical accuracy[2]. Companies like VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Butterfly Network (NYSE:BFLY), Tempus AI (NASDAQ:TEM), RadNet (NASDAQ:RDNT), and GE HealthCare (NASDAQ:GEHC) are conv
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, and Merck, known as MSD outside of the United States and Canada, today announced an expanded, multi-year collaboration aimed at accelerating the discovery and development of precision medicine biomarkers and supporting Merck's oncology and potentially broader therapeutic portfolios. "This collaboration builds on our existing relationship and reflects our shared commitment to harnessing the power of multimodal datasets with AI to deliver better options for patients," said Ryan Fukushima, CEO, Data & Apps at Tempus. "We've spent years configuring our Lens Platform to seamlessly lever
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Morgan Stanley Technology, Media, and Telecom Conference on Tuesday, March 3 in San Francisco. Eric Lefkofsky, Tempus Founder and CEO, will participate in a fireside chat at 9:15 AM PST. The live webcast may be accessed directly using the following link: https://event.webcasts.com/starthere.jsp?ei=1753938&tp_key=e25fc24c17&tp_special=8. A recording will be made available on the Events page of Tempus' Investor Relations website. About Tempus Tempus is a technology company advancing precision medicine through the practical applicati
3 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
Mizuho initiated coverage of Tempus AI with a rating of Outperform and set a new price target of $100.00
Robert W. Baird initiated coverage of Tempus AI with a rating of Outperform and set a new price target of $59.00
Morgan Stanley resumed coverage of Tempus AI with a rating of Overweight and set a new price target of $85.00
Oran Muduroglu, proven medical imaging entrepreneur, to lead U.S. launch of eyonis® LCS Established U.S. commercial and clinical infrastructure combined with Medicare reimbursement pathway already in place to support expansion Active discussions underway to establish key clinical partnerships to support broad access across U.S. lung cancer screening programs Webcasts will be held on February 26, 2026, to discuss the Company's recent achievements and upcoming milestones for eyonis® LCS deployment in the U.S. Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218440005/en/Oran Muduroglu Appointed Presi
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The meeting is taking place November 5 - 9 at the Gaylord National Convention Center in National Harbor, Maryland. "We're excited to join the oncology community at this year's meeting and highlight our latest research and progress in advancing the immuno-oncology field," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "Our latest findings demonstrate the potential of integrated, data-driven approaches to refine biomarkers, im
SC 13G - Tempus AI, Inc. (0001717115) (Subject)
SC 13G - Tempus AI, Inc. (0001717115) (Subject)
SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4652845 United States - New York: (646) 307-1963 USA & Canada - Toll-Free: (800) 715-9871 Live Webcast: https://edge.media-
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 5436492 USA & Canada: Toll-Free (800) 715-9871 United States: Toll (646) 307-1963 Live Webcast: https://edge.media-server.com/mmc/p/vg3azega A
Paige's strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio. Founded in 2017, Paige has developed and deployed several AI applications, including the first FDA-cleared AI application in pathology, allowin